×

Coherus BioSciences to Present at J.P. Morgan Healthcare Conference on January 11

REDWOOD CITY, Calif., Jan. 04, 2016 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), a leading pure-play, global biosimilars company with late-stage clinical products, today announced that it will present at the 34th Annual J.P. Morgan Healthcare Conference on Monday, January 11 at 11:30 am PT in San Francisco, California.

A webcast of the presentation will be available on the Investors page of the Coherus website at http://investors.coherus.com.

About Coherus BioSciences, Inc.

Coherus is a pure-play biosimilar platform company that develops and commercializes high-quality therapeutics for major regulated markets. Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access. Composed of a team of proven industry veterans with world-class expertise in process science, analytical characterization, protein production and clinical-regulatory development, Coherus is positioned as a leader in the global biosimilar marketplace. Coherus is advancing three late-stage clinical products towards commercialization, CHS-1701 (pegfilgrastim biosimilar), CHS-0214 (etanercept biosimilar) and CHS-1420 (adalimumab biosimilar), as well as developing a robust pipeline of future products. For additional information, please visit www.coherus.com.

CONTACT: Keith Vendola, M.D. Investor Relations Coherus BioSciences, Inc. kvendola@coherus.com +1 (650) 437-6239

Source:Coherus BioSciences, Inc.